Pieter van Gageldonk

Mr. Pieter van Gageldonk

National Institute for Public Health and the Environment, De Bilt, The Netherlands

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2008 in Journal of Immunological Methods
Verified
Journal Article
Closed access
PGPieter van Gageldonk
Pieter van Gageldonk
FSFrank G. van Schaijk
Frank G. van Schaijk
FKFiona R. van der Klis
Fiona R. van der Klis
GBGuy A.M. Berbers
Guy A.M. Berbers

1 December 2010 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SGSabine C. de Greeff
Sabine C. de Greeff
HMHester E. de Melker
Hester E. de Melker
PGPieter van Gageldonk
Pieter van Gageldonk
JSJoop F. P. Schellekens
Joop F. P. Schellekens
FKFiona R. M. van der Klis
Fiona R. M. van der Klis
GBGuy A. M. Berbers
Guy A. M. Berbers
In many countries, the reported pertussis has increased despite high vaccination coverage. However, accurate determination of the burden of disease is hampered by reporting artifacts. The infection frequency is more reliably estimated on the basis of the prevalence of high IgG concentrations against pertussis toxin (IgG-Ptx). We determined whether the increase in reported pertussis in the last decade is associated with an increase in the number of infections. In a cross-sectional population-based serosurveillance study conducted in 2006-07, from a randomly selected age-stratified sample of 7,903 persons, serum IgG-Ptx concentrations were analyzed using a fluorescent bead-based multiplex immuno assay. In 2006-07, 9.3% (95%CI 8.5-10.1) of the population above 9 years of age had an IgG-Ptx concentration above 62.5 EU/ml (suggestive for pertussis infection in the past year), which was more than double compared to 1995-96 (4.0%; 95%CI 3.3-4.7). The reported incidence showed a similar increase as the seroprevalence between both periods. Although changes in the vaccination program have reduced pertussis morbidity in childhood, they have not affected the increased infection rate in adolescent and adult pertussis. Indeed, the high circulation of B. pertussis in the latter age-categories may limit the effectiveness of pediatric vaccination.

11 January 2012 in Clinical and Vaccine Immunology
Verified
Journal Article
Open access
PDF file
GSGaby P. Smits
Gaby P. Smits
PGPieter van Gageldonk
Pieter van Gageldonk
LSLeo M. Schouls
Leo M. Schouls
FKFiona R. M. van der Klis
Fiona R. M. van der Klis
GBGuy A. M. Berbers
Guy A. M. Berbers
Enzyme-linked immunosorbent assay (ELISA) is normally used to quantify the amount of serum IgG antibodies against measles, mumps, rubella, and varicella-zoster virus (MMRV). However, this method is time- and material-consuming. Therefore, a multiplex immunoassay for the simultaneous quantitative detection of antibodies against MMRV was developed. In-house as well as commercially available antigens can be used, making the assay available for all laboratories. The multiplex assay is much more sensitive than the separate ELISAs and has a high specificity, and only 5 μl of serum is needed. Heterologous inhibition did not exceed 11.5%, while homologous inhibition varied between 91.3 and 97.9%. Good correlations with the in-house ELISAs for measles (R2= 0.98), mumps (R2= 0.97), and rubella (R2= 0.97) virus as well as with the ELISA kit for varicella-zoster virus (R2= 0.95) were obtained. In conclusion, the MMRV multiplex assay is a good alternative to the conventional ELISAs and suitable for use in serosurveillance and vaccine studies.

19 June 2013 in JAMA
Verified
Journal Article
Closed access
PDF file
MHMarloes W. Heijstek
Marloes W. Heijstek
SKSylvia Kamphuis
Sylvia Kamphuis
WAWineke Armbrust
Wineke Armbrust
JSJoost Swart
Joost Swart
SGSimone Gorter
Simone Gorter
NWNico M. Wulffraat
Nico M. Wulffraat
Research from JAMA — Effects of the Live Attenuated Measles-Mumps-Rubella Booster Vaccination on Disease Activity in Patients With Juvenile Idiopathic Arthritis — A Randomized Trial

1 September 2010 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Closed access
JBJolice P. van Den Berg
Jolice P. van Den Berg
EWElisabeth A. M. Westerbeek
Elisabeth A. M. Westerbeek
GBGuy A. M. Berbers
Guy A. M. Berbers
PGPieter van Gageldonk
Pieter van Gageldonk
FKFiona R. M. van der Klis
Fiona R. M. van der Klis
Ruurd VAN ELBURGRuurd VAN ELBURG
Ruurd VAN ELBURG
Maternal antibodies, transported through the placenta during pregnancy, contribute to the protection of infants from infectious diseases during the first months of life. The aim of this study was to measure the concentration of antibodies against several vaccine-preventable diseases in paired maternal and cord blood serum samples in preterm and term infants and to assess placental transfer ratios and infant antibody concentrations against vaccine-preventable diseases. Antibody concentrations specific against pertussis proteins (pertussis toxin, filamentous hemagglutinin, pertactin, and fimbriae), diphtheria and tetanus toxins, and antibody concentrations specific against polysaccharides from Haemophilus influenzae type b and Neisseria meningitidis serogroup C were measured in cord blood samples from preterm (<32 weeks and 1500 g) and term infants and maternal serum samples, using a fluorescent bead-based multiplex immunoassay. A total of 96 preterm and 42 term infants and their mothers were included in the study. Placental transfer ratios of antibodies against all vaccine antigens were significantly lower in preterm infants (medians varied from 0.26 to 0.86) compared with term infants (medians, 0.74–1.89; all antibodies P < 0.05). Furthermore, polysaccharide-vaccine–specific antibodies showed lower transplacental transport ratios than protein-vaccine–specific antibodies. Maternal concentrations are the most important determinants of infant antibody concentrations against vaccine-preventable diseases. Preterm infants benefit to a lesser extent from maternal antibodies against vaccine-preventable diseases than term infants, posing them at higher risk for infectious diseases in the first months of life.

4 September 2013 in JAMA
Verified
Journal Article
Closed access
PDF file
JSJudith Spijkerman
Judith Spijkerman
RVReinier H. Veenhoven
Reinier H. Veenhoven
AWAlienke J. Wijmenga-Monsuur
Alienke J. Wijmenga-Monsuur
KEKarin E. M. Elberse
Karin E. M. Elberse
PGPieter van Gageldonk
Pieter van Gageldonk
GBGuy A. M. Berbers
Guy A. M. Berbers
Research from JAMA — Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine Administered According to 4 Different Primary Immunization Schedules in Infants — A Randomized Clinical Trial